| Name | Title | Contact Details |
|---|
Swiss-American Products dba as elta Skin and Wounc Care is a Carrollton, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Twine Health is new kind of healthcare technology company that takes a person-centric approach to collaborative care. Most patient-centric paradigms are infected by the age-old assumption that patients are their conditions, and carry the hubris that patients can be "fixed" by throwing resources at them. To us, patients are people, not numbers. We strive to give them tools to easily understand and manage their unique health situation, and enhance relationships with their care teams.
AWAK is a patient-centric medical technology company with a mission to enhance the lives of dialysis patients and their caregivers by providing solutions to deliver better outcomes along with improving their quality of life.
MIGUN USA CORPORATION is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Transgenomic is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is the global leader in cardiac genetic testing with a family of innovative products designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.